1. For the anticancer alkaloid, Taxol®, see: (a) Nicolaou, K. C.; Dai, W.-M.; Guy, R. K. Angew. Chem., Int. Ed. Engl. 1994, 33, 15. (b) Taxane Anticancer Agents, Basic Science and Current Status, ACS Symposium Series 583; Georg, G. I.; Chen, T. T.; Ojima, I.; Vyas, D. M., Eds.; American Chemical Society: Washington, DC, 1995.
2. For the anticancer alkaloid, camptothecin, see: Wall, M. E.; Wani, M. C. In Cancer Chemotherapeutic Agents; Foye, W. O., Ed.; ACS: Washington, DC, 1995; pp. 293–310.
3. (a) Catalytic Asymmetric Synthesis; Ojima, I., Ed.; VCH Publishers: New York, 1993. (b) Noyori, R. Asymmetric Catalysis in Organic Synthesis; John Wiley & Sons: New York, 1994. (c) Enantioselective Synthesis; Gladysz, J. A.; Michl, J., Eds.; Chem. Rev. 1992; Vol. 92, No. 5. (d) Seyden-Penne, J. Chiral Auxiliaries and Ligands in Asymmetric Synthesis; John Wiley & Sons: New York, 1995. (e) Advances in Catalytic Processes; Doyle, M. P., Ed.; JAI Press: Greenwich, 1995. (f) Handbook of Enantioselective Catalysis; Brunner, H.; Zettlmeier, W., Eds.; VCH Publishers: New York, 1993; Vols. 1–2.
4. Johnson, R. A.; Sharpless, K. B. In Catalytic Asymmetric Synthesis; Ojima, I., Ed.; VCH Publishers: New York, 1993; pp. 227–272.
5. Dictionary of Organic Compounds, 5th ed.; Buckingham, J., Ed.; Chapman and Hall: New York, 1982; p. 4084.